Zentalis Pharmaceuticals (ZNTL) Net Income towards Common Stockholders (2019 - 2026)
Zentalis Pharmaceuticals' quarterly Net Income towards Common Stockholders came in at -$35.4 million in Q1 2026, up 26.78% year-on-year from -$27.9 million in Q1 2025, and little changed quarter-over-quarter from -$35.2 million in Q4 2025.
Zentalis Pharmaceuticals has reported Net Income towards Common Stockholders for 8 years, with the latest figure at -$35.4 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 26.78% year-over-year to -$35.4 million; the trailing twelve-month figure through Mar 2026 stood at -$124.1 million (up 44.63% YoY), and the FY2025 full-year result was -$137.1 million, up 17.37% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$35.4 million, roughly flat from -$35.2 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $10.0 million in Q1 2024, with the low at -$99.0 million in Q2 2023.
- Average Net Income towards Common Stockholders over 5 years is -$49.2 million, with a median of -$48.4 million recorded in 2022.
- Year-over-year, Net Income towards Common Stockholders surged 116.42% in 2024 and tumbled 580.87% in 2025.
- Tracing ZNTL's Net Income towards Common Stockholders over 5 years: stood at -$48.4 million in 2022, then retreated by 26.17% to -$61.0 million in 2023, then advanced by 22.24% to -$47.5 million in 2024, then gained by 25.82% to -$35.2 million in 2025, then fell by 0.39% to -$35.4 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$35.4 million (Q1 2026), -$35.2 million (Q4 2025), and -$26.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Zentalis Pharmaceuticals | 280.35 Mn | 280.35 Mn | - | -35.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.35 Mn |
| Dec 31, 2025 | -35.22 Mn |
| Sep 30, 2025 | -26.69 Mn |
| Jun 30, 2025 | -26.87 Mn |
| Mar 31, 2025 | -48.28 Mn |
| Dec 31, 2024 | -47.47 Mn |
| Sep 30, 2024 | -40.16 Mn |
| Jun 30, 2024 | -88.28 Mn |
| Mar 31, 2024 | 10.04 Mn |
| Dec 31, 2023 | -61.05 Mn |
| Sep 30, 2023 | -55.67 Mn |
| Jun 30, 2023 | -99.00 Mn |
| Mar 31, 2023 | -61.13 Mn |
| Dec 31, 2022 | -48.38 Mn |
| Sep 30, 2022 | -52.13 Mn |
| Jun 30, 2022 | -63.05 Mn |
| Mar 31, 2022 | -57.49 Mn |
| Dec 31, 2021 | -48.79 Mn |
| Sep 30, 2021 | -10.49 Mn |
| Jun 30, 2021 | -55.06 Mn |
| Mar 31, 2021 | -50.44 Mn |
| Dec 31, 2020 | -65.15 Mn |
| Sep 30, 2020 | -34.67 Mn |
| Jun 30, 2020 | -27.29 Mn |
| Mar 31, 2020 | -16.24 Mn |
| Dec 31, 2019 | -14.55 Mn |
| Sep 30, 2019 | -12.57 Mn |
| Jun 30, 2019 | -10.60 Mn |
| Mar 31, 2019 | -8.66 Mn |